FDA Approves New Molecularly Targeted Therapeutic for Non-Hodgkin Lymphoma

The flurry of treatments approved by the U.S. Food and Drug Administration (FDA) for treating hematological malignancies continued last week with the approval of the molecularly targeted therapeutic copanlisib (Aliqopa) for the treatment of certain adults with non-Hodgkin lymphoma.

Read More

FDA Approves Two New Treatments for Acute Myeloid Leukemia

This week, the U.S. Food and Drug Administration (FDA) added two new treatments to the armamentarium for hematologic oncologists treating certain groups of patients with acute myeloid leukemia (AML): enasidenib (Idhifa) and Vyxeos. This news is particularly welcome because AML is the form of leukemia with the lowest five-year relative survival rate.

Read More